Theravance Biopharma (TBPH) Total Current Liabilities (2013 - 2026)

Theravance Biopharma (TBPH) has reported Total Current Liabilities for 14 consecutive years, with $31.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 0.87% year-over-year to $31.8 million; the TTM figure through Mar 2026 stood at $31.8 million (up 0.87% YoY), while the FY2025 annual figure was $38.3 million, up 19.38% from the prior year.
• Total Current Liabilities fell to $31.8 million in Q1 2026 per TBPH's latest filing, from $38.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $142.1 million in Q3 2022 and bottomed at $21.7 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $37.8 million across 5 years, with a median of $31.5 million in 2025.
• Annual changes were most pronounced in 2023 — Total Current Liabilities plunged 82.15% — and 2025, when it jumped 138.09%.
• Theravance Biopharma's Total Current Liabilities stood at $28.7 million in 2022, then dropped by 13.75% to $24.8 million in 2023, then climbed by 29.55% to $32.1 million in 2024, then advanced by 19.38% to $38.3 million in 2025, then retreated by 17.04% to $31.8 million in 2026.
• Business Quant data shows TBPH's Total Current Liabilities at $31.8 million in Q1 2026, $38.3 million in Q4 2025, and $37.4 million in Q3 2025.